Vanda Pharmaceuticals Inc. (VNDA)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 4.6300 |
| Open | 4.6300 |
| Bid | 4.5400 x 300 |
| Ask | 4.6000 x 100 |
| Day's range | 4.5508 - 4.6700 |
| 52-week range | 3.3000 - 7.0000 |
| Volume | |
| Avg. volume | 2,364,491 |
| Market cap | 262.371M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 114.00 |
| EPS (TTM) | 0.0400 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.25 |
ZacksVanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
Vanda Pharmaceuticals (VNDA) reachead $4.56 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.
ZacksVanda (VNDA) to Report Q1 Earnings: What's in the Cards?
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.
PR NewswireVanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp.
© 2024 Yahoo. All rights reserved.